Navigation Links
Beckman Coulter Announces First Quarter 2008 Results
Date:4/30/2008

d

2008 2007

Cash flows from operating activities

Net earnings $42.9 $37.1

Adjustments to reconcile net earnings

to net cash provided by operating activities

Depreciation and amortization 59.2 48.5

Provision for doubtful accounts receivable 1.0 2.0

Share-based compensation expense 9.5 6.1

Tax benefits from exercises of

share-based payment awards 2.3 9.4

Excess tax benefits from share-based

payment transactions (2.3) (8.8)

Gain on sale of building and land (2.6) -

Deferred income taxes 4.2 (1.3)

Changes in assets and liabilities

Trade and other receivables 15.0 37.3

Inventories (31.5) (33.3)

Accounts payable and accrued expenses (38.6) (12.1)

Income taxes payable (7.3) (16.6)

Long-term lease receivables 2.3 4.0

Other 8.0 (2.2)

Net cash provided by operating activities 62.1 70.1

Cash flows from investing activities

Additions to property, plant and equipment (65.0) (64.5)

Proceeds from sale of building and land 3.0 -

Payments for business acquisitions and

technology licenses (14.2) (10.8)

Net cash used in investing activities (76.2) (75.3)

Cash flows from financing activities

Dividends to
'/>"/>

SOURCE Beckman Coulter, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related biology technology :

1. Beckman Coulter Acquires Rights to Hepatitis C Virus
2. Beckman Coulter Declares Quarterly Dividend Payout of $0.17 Per Share
3. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
4. Beckman Coulter to Present at the 2008 Bear Stearns London Healthcare Conference
5. Beckman Coulter Releases the High-Volume UniCel(R) DxC 880i Integrated Work Cell
6. AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards
7. Beckman Coulter to Present at the JPMorgan Healthcare Conference
8. Beckman Coulter Elects AMN Healthcare Executive to Board of Directors
9. Beckman Coulter to Acquire Exclusive Rights to Break-Through Technologies
10. Beckman Coulter to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Beckman Coulter to Present at the 19th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Rockville, MD (PRWEB) September 17, 2014 ... Small Business Innovation Research (SBIR) grant to support the ... award will provide ITI with approximately $255,000 over one ... a leading cause of food allergy, affect over one ... anaphylaxis behind peanut allergy. Tree nut exposure is also ...
(Date:9/17/2014)... , Sept. 17, 2014 Intarcia Therapeutics, ... data from a study of the cost and predictability ... 50 th Annual Meeting of the European Association ... session today, Christian Frois , Ph.D., of Analysis ... series of planned Intarcia-sponsored, retrospective studies to characterize the ...
(Date:9/17/2014)... LAUDERDALE, Fla. , Sept. 17, 2014 Alternative ... an agreement to form a Special Purpose Vehicle in partnership ... based Jatropha centric agro energy company. The SPV shall be ... registered entity with AFAI as majority shareholder. The SPV shall ... Africa , particularly Ethiopia . ...
(Date:9/17/2014)... FRANCISCO, Calif. , Sept. 17, 2014 ... a molecular diagnostics company pioneering the field of molecular ... to chief operating officer. Mr. Hall joined ... the company,s commercial entry into endocrinology. Since 2012, he ... as well as managed care and billing functions. As ...
Breaking Biology Technology:Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4
... This release is available in German . ... magic word in electronics. Dr. Willi Auwaerter and Professor Johannes ... Universitaet Muenchen (TUM), have now presented a novel molecular switch ... functionality of the switch is the position of a single ...
... Therapeutics, Inc. today announced that Ivan Bergstein, MD, the ... the Oppenheimer 22nd Annual Healthcare Conference on Wednesday, December ... Astoria Hotel in New York City. ... Inc. is a clinical stage biopharmaceutical company developing novel ...
... 2011 Syndax Pharmaceuticals, Inc. announced today ... study, demonstrated entinostat, a novel, oral small molecule inhibitor ... single agent in patients with relapsed or refractory Hodgkin,s ... 11, from 6:00 to 8:00 PM PT at the ...
Cached Biology Technology:The smallest conceivable switch 2Stemline Therapeutics, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference 2Entinostat Demonstrates Activity in Hodgkin's Lymphoma 2Entinostat Demonstrates Activity in Hodgkin's Lymphoma 3Entinostat Demonstrates Activity in Hodgkin's Lymphoma 4Entinostat Demonstrates Activity in Hodgkin's Lymphoma 5
(Date:9/17/2014)... Transmission of bacterial infections, including MRSA and MSSA ... microscopic bumps that mimic the scaly surface of ... open access journal Antimicrobial Resistance and Infection ... different materials prevented the spread of human disease ... named Sharklet, is an arrangement of ridges formulated ...
(Date:9/16/2014)... North American Menopause Society (NAMS) has published its ... midlife womenon everything from hot flashes to heart ... Society Recommendations for Clinical Care of Midlife Women," ... Menopause . This is the first, comprehensive ... midlife women freely available to all clinicians who ...
(Date:9/16/2014)... 36 Pit Fire began on September 13, 2014. The ... It is currently over 2,300 acres in size and is ... 36 Pit Fire was calm Monday night due to higher ... an anchor point and beginning to construct a fireline on ... following resources are working on the fire: , 7 20-person ...
Breaking Biology News(10 mins):Sharks' skin has teeth in the fight against hospital superbugs 2
... launched a key initiative to keep Europe at the forefront ... cell therapies to restore lost, damaged, or ageing cells and ... body,s ,master cells, that have not yet been programmed to ... of stem cells, and it is becoming clear that if ...
... (TWIC) Program, Ensures No Fraudulent Duplicate Enrollments ... Fla., June 17 ID Solutions, Inc., ... trusted,credential assurance, reported that it has been ... the Transportation Security Agency,s (TSA,s),TWIC program. The ...
... its latest state of the environment report, released ... environmental issues facing the NAFTA partners. The ... biodiversity and ecosystems, and pollution. Specific topics include ... vaquita porpoiseand the quality and quantity of water ...
Cached Biology News:European Science Foundation aims to strengthen 'regenerative medicine' 2ID Solutions Awarded Full-Production Order for Fingerprint Processing Software for TWIC 2New report looks at the state of the North American environment 2
... precision pressure regulator and pressurized syringe holder for ... Steady flow rate Microinjecting Fine ... Can be added to any new or existing ... manufacturer, even homemade. Connect to house air or ...
Chicken polyclonal to UCK2 ( Abpromise for all tested applications). Antigen: Full length protein, corresponding to amino acids 1-261 of Human UCK2 Entrez Gene ID: 7371 Swiss Protein ID: ...
Physical Form: powder Color: white Removes FLAG peptide from N-terminal and Met-N-terminal fusion proteins. Supplied with optimized enterokinase buffer....
Features , Designed to assist users in applying domed caps to tube strips and plates , Minimises the pressure required to seal the caps effectively , Enables multiple tubes to be sealed simultaneousl...
Biology Products: